Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel Free ETHZ Stock Alerts

Flag Ship Acquisition (ETHZ) Competitors

Flag Ship Acquisition logo
$5.49 -0.36 (-6.15%)
As of 05/4/2026
Compare

ETHZ vs. FBRX, AGMB, IVVD, NAGE, and PBYI

Should you be buying Flag Ship Acquisition stock or one of its competitors? The main competitors of Flag Ship Acquisition include Forte Biosciences (FBRX), AgomAb Therapeutics (AGMB), Invivyd (IVVD), Niagen Bioscience (NAGE), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.

How does Flag Ship Acquisition compare to Forte Biosciences?

Flag Ship Acquisition (NASDAQ:ETHZ) and Forte Biosciences (NASDAQ:FBRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Flag Ship Acquisition has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flag Ship Acquisition$4.11M25.39-$6.17M-$159.65N/A
Forte BiosciencesN/AN/A-$69.38M-$4.77N/A

Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 145.51%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than Flag Ship Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Forte Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Flag Ship Acquisition has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500.

In the previous week, Forte Biosciences had 3 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 3 mentions for Forte Biosciences and 0 mentions for Flag Ship Acquisition. Forte Biosciences' average media sentiment score of 1.11 beat Flag Ship Acquisition's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Flag Ship Acquisition Neutral
Forte Biosciences Positive

4.1% of Flag Ship Acquisition shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 15.1% of Flag Ship Acquisition shares are held by insiders. Comparatively, 5.9% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Forte Biosciences' return on equity of -98.36% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Flag Ship AcquisitionN/A -185.71% -83.12%
Forte Biosciences N/A -98.36%-82.81%

Summary

Forte Biosciences beats Flag Ship Acquisition on 10 of the 14 factors compared between the two stocks.

How does Flag Ship Acquisition compare to AgomAb Therapeutics?

Flag Ship Acquisition (NASDAQ:ETHZ) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

AgomAb Therapeutics has lower revenue, but higher earnings than Flag Ship Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flag Ship Acquisition$4.11M25.39-$6.17M-$159.65N/A
AgomAb TherapeuticsN/AN/AN/AN/AN/A

AgomAb Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 156.00%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe AgomAb Therapeutics is more favorable than Flag Ship Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 1 mentions for AgomAb Therapeutics and 0 mentions for Flag Ship Acquisition. Flag Ship Acquisition's average media sentiment score of 0.00 equaled AgomAb Therapeutics'average media sentiment score.

Company Overall Sentiment
Flag Ship Acquisition Neutral
AgomAb Therapeutics Neutral

4.1% of Flag Ship Acquisition shares are held by institutional investors. 15.1% of Flag Ship Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AgomAb Therapeutics' return on equity of 0.00% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Flag Ship AcquisitionN/A -185.71% -83.12%
AgomAb Therapeutics N/A N/A N/A

Summary

AgomAb Therapeutics beats Flag Ship Acquisition on 6 of the 9 factors compared between the two stocks.

How does Flag Ship Acquisition compare to Invivyd?

Flag Ship Acquisition (NASDAQ:ETHZ) and Invivyd (NASDAQ:IVVD) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Flag Ship Acquisition has a net margin of 0.00% compared to Invivyd's net margin of -98.25%. Invivyd's return on equity of -48.65% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Flag Ship AcquisitionN/A -185.71% -83.12%
Invivyd -98.25%-48.65%-34.48%

4.1% of Flag Ship Acquisition shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 15.1% of Flag Ship Acquisition shares are held by company insiders. Comparatively, 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Flag Ship Acquisition has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flag Ship Acquisition$4.11M25.39-$6.17M-$159.65N/A
Invivyd$53.43M7.36-$52.49M-$0.32N/A

Flag Ship Acquisition has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Invivyd has a consensus target price of $8.00, suggesting a potential upside of 475.54%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Flag Ship Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Invivyd
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Invivyd had 2 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 2 mentions for Invivyd and 0 mentions for Flag Ship Acquisition. Flag Ship Acquisition's average media sentiment score of 0.00 equaled Invivyd'saverage media sentiment score.

Company Overall Sentiment
Flag Ship Acquisition Neutral
Invivyd Neutral

Summary

Invivyd beats Flag Ship Acquisition on 9 of the 15 factors compared between the two stocks.

How does Flag Ship Acquisition compare to Niagen Bioscience?

Flag Ship Acquisition (NASDAQ:ETHZ) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

4.1% of Flag Ship Acquisition shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 15.1% of Flag Ship Acquisition shares are owned by insiders. Comparatively, 9.4% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Niagen Bioscience has a net margin of 13.43% compared to Flag Ship Acquisition's net margin of 0.00%. Niagen Bioscience's return on equity of 21.10% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Flag Ship AcquisitionN/A -185.71% -83.12%
Niagen Bioscience 13.43%21.10%14.92%

Niagen Bioscience has a consensus target price of $15.00, indicating a potential upside of 211.20%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than Flag Ship Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Niagen Bioscience has higher revenue and earnings than Flag Ship Acquisition. Flag Ship Acquisition is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flag Ship Acquisition$4.11M25.39-$6.17M-$159.65N/A
Niagen Bioscience$129.42M2.97$17.38M$0.2024.10

Flag Ship Acquisition has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500.

In the previous week, Niagen Bioscience had 1 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 1 mentions for Niagen Bioscience and 0 mentions for Flag Ship Acquisition. Flag Ship Acquisition's average media sentiment score of 0.00 equaled Niagen Bioscience'saverage media sentiment score.

Company Overall Sentiment
Flag Ship Acquisition Neutral
Niagen Bioscience Neutral

Summary

Niagen Bioscience beats Flag Ship Acquisition on 13 of the 15 factors compared between the two stocks.

How does Flag Ship Acquisition compare to Puma Biotechnology?

Flag Ship Acquisition (NASDAQ:ETHZ) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Puma Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Puma Biotechnology had 1 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 1 mentions for Puma Biotechnology and 0 mentions for Flag Ship Acquisition. Flag Ship Acquisition's average media sentiment score of 0.00 equaled Puma Biotechnology'saverage media sentiment score.

Company Overall Sentiment
Flag Ship Acquisition Neutral
Puma Biotechnology Neutral

Flag Ship Acquisition has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.

4.1% of Flag Ship Acquisition shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 15.1% of Flag Ship Acquisition shares are held by company insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Puma Biotechnology has a net margin of 13.62% compared to Flag Ship Acquisition's net margin of 0.00%. Puma Biotechnology's return on equity of 27.80% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Flag Ship AcquisitionN/A -185.71% -83.12%
Puma Biotechnology 13.62%27.80%15.35%

Puma Biotechnology has higher revenue and earnings than Flag Ship Acquisition. Flag Ship Acquisition is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flag Ship Acquisition$4.11M25.39-$6.17M-$159.65N/A
Puma Biotechnology$228.40M1.64$31.11M$0.6112.05

Summary

Puma Biotechnology beats Flag Ship Acquisition on 12 of the 13 factors compared between the two stocks.

Get Flag Ship Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for ETHZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETHZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ETHZ vs. The Competition

Export
MetricFlag Ship Acquisition IndustryManufacturing SectorNASDAQ Exchange
Market Cap$67.11M$2.91B$4.20B$11.76B
Dividend YieldN/A15.26%5.87%5.26%
P/E Ratio-0.0313.1623.3927.07
Price / Sales25.392,020.73155.6473.40
Price / CashN/A25.6252.0853.90
Price / Book0.193.4337.876.69
Net Income-$6.17M-$42.77M$114.66M$332.64M
7 Day Performance6.81%1.44%2.30%3.07%
1 Month Performance99.64%5.17%5.42%7.80%
1 Year PerformanceN/A20.17%19.21%41.57%

Flag Ship Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ETHZ
Flag Ship Acquisition
N/A$5.49
-6.2%		N/AN/A$67.11M$4.11MN/A7
FBRX
Forte Biosciences
3.2097 of 5 stars		$28.03
+6.2%		$67.00
+139.0%		+309.8%$389.23MN/AN/A5
AGMB
AgomAb Therapeutics
N/A$10.74
+0.9%		$32.00
+198.0%		N/A$389.19MN/AN/A62
IVVD
Invivyd
1.9309 of 5 stars		$1.36
-1.4%		$8.00
+488.2%		+141.6%$384.61M$53.43MN/A100
NAGE
Niagen Bioscience
3.3234 of 5 stars		$4.76
-1.7%		$16.00
+236.1%		-43.0%$381.18M$129.42M23.80120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ETHZ) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
When the PC replaced the mainframe, companies that missed the shift went bankrupt. George Gilder - who called ...
Eagle Publishing | Sponsoredtc pixel
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...
Banyan Hill Publishing | Sponsoredtc pixel